维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

18篇 您的检索式：作者名="DEWIED D"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Neuropeptides, food intake and body weight regulation: A hypothalamic focus显示文摘	HILLEBRAND J J G DEWIED D ADAN R A H	2002	Peptides2002，23，：	1
	2	Central target for the behavioural effects of vasopressin neuropeptides显示文摘	Dewied D Gafforio Vanree J M	1984	Nature1984，308，：	1
	3	Requirement for ERK1/2 activation in the regulation of progesterone production in human granulosa-lutein cells is stimulus specific显示文摘	Dewi D A Abayasekara D R E Wheeler-Jones C P D	2001	J Clin Endocrinol Metab2001，86，：	1
	4	Duplicate record elimination in large data files显示文摘	Hon D B Dewi V J	1995	ACM Transactions on Database Sys- tem1995，，：	1
	5	Prognostic effect of weight loss prior to chemotherapy in cancer patients显示文摘	Dewys W D Begg C Lavin P T	1980	Am J Med1980，69，4：	1
	6	Prognostic effect of weight loss prior to chemotherapy in cancer patients显示文摘	DEWYS W D BEGG C LAVIN P T	1980	Am J Med1980，69，：	1
	7	Duplicate record elimination in large data files显示文摘	Hon D B Dewi V J	1995	ACM Transactions on Database Sys tem1995，，：	1
	8	Prognostic effect of weight loss prior to chemotherapy in cancer patients显示文摘	DeWys WD Begg D Lavin PT	1980	Am J Med1980，69，4：	1
	9	Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma显示文摘	Dewi A Farida L Ashraf D	2001	Am J Hum Genet2001，69，1：	1
	10	Cancer stem cell theory in gas- trointestinal malignancies: recent progress and upcoming challenges 显示文摘	Dewi D L Ishii H Kano Y	2011	Gastroenterol2011，46，10：	1
	11	Prognostic effect of weight loss prior to chemotherpy in cancer patients显示文摘	Dewys W D Begg C Lavin P T	1980	Am J Med1980，69，：	1
	12	Prognostic effect of weight loss prior to chemotherapy in cancer patients显示文摘	Dewys W D Begg C Lavin PT	1980	Am J Med1980，69，4：	1
	13	Vasopressin antagoniss block peripheral as well as central vasopressin receptors 显示文摘	DEWIED D GAFFORI O VANREE J M	1984	Pharmacol Biochem Behav1984，21，：	1
	14	PEPCK coordinates the regulation of centralcarbon metabolism to promote cancer cell growth显示文摘	Montal E D Dewi R Bhalla K	2015	Mol Cell2015，60，4：	1
	15	Effect of defibrination on tumor growth and response to chemotherapy显示文摘	William D DeWys Hau C	1976	Cancer Res1976，36，：	1
	16	Prognostic effect of weight loss prior to chemotherapy in cancer patients 显示文摘	Dewys W D Begg C Lavin P T	1980	Am J Med1980，69，4：	1
	17	Comparison of the strength of barncle and commercial dental cements显示文摘	Despain R R Dewies K L Luntz R D	1973	J Dent Res1973，52，4：	1
	18	FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study显示文摘BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy(L1)in advanced pancreatic ductal adenocarcinoma(aPDAC).FOLFOXIRI,a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil,has demonstrated efficacy and feasibility in colorectal cancer.AIM To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical practice.METHODS Analyses were derived from all consecutive aPDAC patients treated in L1 between January 2011 and December 2017 in two French institutions,with either FOLFOXIRI(n=165)or FOLFIRINOX(n=124)regimens.FOLFOXIRI consisted of irinotecan(165 mg/m2),oxaliplatin(85 mg/m2),leucovorin(200 mg/m2)and 5-fluorouracil(3200 mg/m2 as a 48-h continuous infusion)every 2 wk.Ninety-six pairs of patients were selected through propensity score matching,and clinical outcomes of the two treatment regimens were compared.RESULTS Median overall survival was 11.1 mo in the FOLFOXIRI and 11.6 mo in the FOLFIRINOX cohorts,respectively.After propensity score matching,survival rates remained similar between the two regimens in terms of overall survival(hazard ratio=1.22;P=0.219)and progression-free survival(hazard ratio=1.27;P=0.120).The objective response rate was 37.1%in the FOLFOXIRI group vs 47.8%in the FOLFIRINOX group(P=0.187).Grade 3/4 toxicities occurred in 28.7%of patients in the FOLFOXIRI cohort vs 19.5%in the FOLFIRINOX cohort(P=0.079).FOLFOXIRI was associated with a higher incidence of grade 3/4 digestive adverse events.Hematopoietic growth factors were used after each chemotherapy cycle and the low hematological toxicity rates were below 5%with both regimens.CONCLUSION FOLFOXIRI is feasible in L1 in patients with aPDAC but does not confer any therapeutic benefit as compared with FOLFIRINOX.The low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors.	Angélique Vienot Hortense Chevalier Clément Bolognini Elisabeta Gherga Elodie Klajer Aurélia Meurisse Marine Jary Stefano Kim Christelle d’Engremont Thierry Nguyen Fabien Calcagno Hamadi Almotlak Francine Fein Meher Nasri Syrine Abdeljaoued Anthony Turpin Christophe Borg Dewi Vernerey	2020	World Journal of Gastrointestinal Oncology2020，12，3：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费